The first analysis of the IMPACT trial concluded that patients with BRCA2 PVs have elevated levels of serum prostate specific antigen (PSA) at diagnosis, predominantly high Gleason tumours, increased rates of nodal and distant metastases, and finally high recurrence rates [83]. This evidence concerns the gene BRCA2 and neoplasm.